Connect with us

Technology

Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology

Published

on

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).The collaboration is in line with Orexo’s strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®.

UPPSALA, Sweden, April 10, 2025 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.

The data was generated under the collaboration between Orexo and Abera Biosciences (“Abera”) entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo’s powder-based drug delivery technology AmorphOX with Abera’s innovative and patented vaccine platform BERA™.

The proof-of-concept study was conducted in rats where Abera’s influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo’s AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder.

An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.

Robert Rönn, SVP and Head of R&D, comments: “We are pleased by these results providing us with important proof-of-concept data for a vaccine formulated in our proprietary powder-based drug delivery technology AmorphOX. The potential benefits from formulating vaccines in powder form are significant, as they can reach so many more patients worldwide. The study results represent an important milestone in our continued efforts to develop new and innovative drugs.”

“It is very encouraging to see that our vaccines perform well in both liquid and powder forms. Powder formulations offer significant advantages in future pandemic scenarios, particularly in terms of simplified logistics, thermal stability, and the potential for self-administration during mass vaccination campaigns. Orexo’s AmorphOX technology is an innovative platform that appears to preserve the immunogenic properties of our vaccine,” says Mats Lundgren, CSO of Abera Bioscience.

For further information contact:

Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
Robert Rönn, SVP and Head of R&D
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.

On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm’s main list and is available as  ADRs on OTCQX market (ORXOY) in the US.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.

About AmorphOX® 

Orexo’s proprietary drug delivery platform, AmorphOX, is a powder made up of particles that

are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. 

About Abera Bioscience

Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and Stockholm University. Abera develops innovative vaccines based on proprietary and patented platform technologies. The vaccine candidates can be administered as nasal sprays and are fast and cost-effective to develop and produce. Using its platform technologies, the company has developed several vaccine candidates and is currently focused on two main areas: pneumococcal vaccines and pandemic preparedness. The company’s lead candidate, Ab-01.12, is a nasal vaccine against pneumococci, being prepared for Phase 1 clinical trials.

For more information on Orexo, www.aberabio.com

About BERA™

Abera’s BERA™ vaccine platform is based on bacterial particles known as OMVs (Outer Membrane Vesicles), which are decorated with a large number of disease-specific antigens. Vaccines based on the BERA platform can be administered as nasal sprays and create protection in both mucosal membranes and systemically in the body, aiming to protect against both disease and transmission. The platform technology that enables the rapid development of new vaccine candidates as antigens can be replaced in a plug-and-play manner.

The information was submitted for publication at 8.00 am CET on April 10, 2025. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-announces-positive-data-for-powder-based-intranasal-vaccine-formulated-with-the-amorphox-techn,c4133913

The following files are available for download:

https://mb.cision.com/Main/694/4133913/3380119.pdf

Orexo_PR_ Positive data for powder-based intranasal vaccine candidate_Publ April 10 2025

View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-positive-data-for-powder-based-intranasal-vaccine-formulated-with-the-amorphox-technology-302425436.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

JAMS Launches AI for Enterprise Job Scheduling: JAX and JAMS MCP, on the Model You Choose

Published

on

By

A new AI agent and an open-standard connector let IT teams query, diagnose, and manage automation in plain language, on the model they choose, with operational data staying inside their own network

LONDON, July 24, 2026 /PRNewswire/ — JAMS Software, an orchestration solution for scheduled and event-driven automation, today announced the general availability of two AI capabilities for enterprise job scheduling: JAX, an AI agent built into the JAMS Web Client, and JAMS MCP, a connector built on the open Model Context Protocol standard that brings JAMS into external AI coding tools. Both capabilities ship at no additional cost as part of JAMS Web.

Automation environments grow faster than the teams that run them. Jobs multiply across SQL Server, Azure Data Factory, Airflow, SAP, JDE, and Banner, and when one fails, finding the root cause often means searching several consoles at once, frequently outside business hours. At the same time, IT leaders carry pressure to adopt AI while staying accountable for where operational data goes. JAX and JAMS MCP close both gaps together.

Full details on how JAX and JAMS MCP work, including the control model behind every action, are available at jamsscheduler.com/product/ai.

JAX is an AI agent that runs inside the JAMS Web Client. It finds jobs, troubleshoots failures, and answers how-to questions in plain language, with each response grounded in the JAMS user guide and checked against a built-in glossary. JAX acts only when a user asks it to. Reads flow freely, and every write action pauses for the user’s explicit approval before it runs. JAX does not learn between sessions, and conversations are not retained on the server.

JAMS MCP is a connector, built on the open Model Context Protocol standard, that brings JAMS into the AI tools engineering teams already use, including Cursor, VS Code with Copilot, Claude Code, Claude Desktop, and Codex. Users query jobs, investigate failures, and manage runs in plain language without leaving their tool.

Both capabilities run inside the customer’s own network and act as the signed-in user, with that user’s exact JAMS permissions. There is no elevated AI account: whatever a user cannot do in the JAMS interface, JAX and JAMS MCP cannot do on that user’s behalf. Every JAX and MCP operation is recorded in its own dedicated log, and changes made through the JAMS API land in the JAMS audit trail like any other change. Customers choose their own AI model, whether a commercial provider such as OpenAI or Anthropic or a model running entirely on their own hardware, and JAMS never trains on customer data. In the current release, neither feature edits or deletes a job, folder, schedule, or agent definition. For teams that must keep operational data within a defined boundary, JAX runs on a local model entirely inside the customer’s own network, so nothing leaves at all.

“Adopting AI usually means giving something up, most often visibility into where your data goes,” said Pete Hegland, Chief Executive Officer of JAMS Software. “We built JAX and JAMS MCP so that trade does not have to happen. Every action runs as the signed-in user, every change waits for approval, and the model itself can run entirely inside your own network.”

“IT teams across the United Kingdom and EMEA tell us the same thing: they want the benefit of AI without losing sight of where their data goes,” said Greg McLaughlin, Account Executive for EMEA at JAMS Software. “JAX and JAMS MCP let them keep operational data inside their own network and still get answers in plain language. That combination is what makes this practical for the teams I work with.”

JAX and JAMS MCP are available now to all JAMS Web customers across the United Kingdom and EMEA, with no separate licence, SKU, or additional cost. AI-assisted creation of new jobs and workflows from a plain-language description is on the roadmap for a future release, gated by the same approvals and permissions as every other action.

Learn how JAX and JAMS MCP work at https://jamsscheduler.com/product/ai.

Fast facts

JAX is an AI agent built into the JAMS Web Client for job scheduling and workflow automation.JAMS MCP is a connector built on the open Model Context Protocol standard, for Cursor, VS Code with Copilot, Claude Code, Claude Desktop, and Codex.Both act as the signed-in user, with that user’s exact JAMS permissions, and there is no elevated AI account.Customers choose the AI model, including a local model that runs entirely inside their own network.JAMS never trains on customer data.Both are available now at no additional cost as part of JAMS Web.

About JAMS Software

Founded in 1987, JAMS Software is an orchestration solution that helps IT teams centralize, automate, and manage scheduled and event-driven jobs across complex, hybrid environments. Over 850 customers rely on JAMS to run their automated workloads. JAMS Software, LLC is headquartered at 108 Patriot Drive, Suite A, Middletown, DE 19709.

Media Contact
Bobby Schmidt, Vice President of Marketing
press@jamssoftware.com
800.261.4267

 

 

Logo – https://mma.prnewswire.com/media/3007577/JAMS_logo.jpg
Photo – https://mma.prnewswire.com/media/3007578/jams_jax_ai_agent_job_scheduling_1.jpg
Photo – https://mma.prnewswire.com/media/3007579/jams_jax_mcp_ai_control_model.jpg
Photo – https://mma.prnewswire.com/media/3007580/jams_mcp_ai_connector_claude_cursor.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jams-launches-ai-for-enterprise-job-scheduling-jax-and-jams-mcp-on-the-model-you-choose-302833908.html

Continue Reading

Technology

Video: CNPC offers green chemical answer

Published

on

By

BEIJING, July 24, 2026 /PRNewswire/ — A news report from chinadaily.com.cn:

Located on the edge of the Taklamakan Desert in Northwest China’s Xinjiang Uygur autonomous region, the Tarim 1.2 MTA Phase II Ethylene Project and its supporting green and low-carbon demonstration facility of PetroChina Dushanzi Petrochemical Company, a subsidiary of China National Petroleum Corporation, are offering a new example of China’s low-carbon industrial transformation.

Watch the video to discover how CNPC is exploring a cleaner and more circular future for the industry.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/video-cnpc-offers-green-chemical-answer-302834036.html

SOURCE chinadaily.com.cn

Continue Reading

Technology

Shanghai Electric showcases embodied intelligence robot matrix and AI-native smart factory solutions at WAIC 2026

Published

on

By

Featuring humanoid robots with 41 degrees of freedom, pipe‑inspection robots with ±1mm positioning accuracy, and 51 industrial‑grade AI agents

SHANGHAI, July 24, 2026 /PRNewswire/ — Operations in high-end equipment manufacturing often involve confined spaces, complex objects, and fine manipulation tasks that demand sustained and stable precision. At the recent 2026 World Artificial Intelligence Conference and High-Level Meeting on Global AI Governance (WAIC 2026), Shanghai Electric (SEHK: 02727, SSE: 601727) showcased its comprehensive portfolio of embodied intelligence solutions tailored to a range of industrial scenarios.

Themed “AI for All: Smart Squad, Shining Without Limits,” Shanghai Electric highlighted its capabilities across embodied AI robots, robot core components, and AI-native smart factory solutions, demonstrating end-to-end capabilities spanning complete robot systems, critical parts, industrial software, and smart factory architecture.

“The true value of embodied intelligence lies in understanding real industrial tasks: combining the strength, precision, and stability of machines with human experience and judgment to drive a genuine paradigm of ‘machine-assisted, human-machine collaboration,'” said Wang Chunlei, deputy general manager of the Robotics Business Unit at Shanghai Electric Automation Group.

Shanghai Electric’s robotics portfolio covers five key industrial scenarios: connector insertion, electrical operations, flexible sorting, intelligent assembly, and pipe processing. Highlights include:

“SUYUAN” bipedal humanoid robot: With 41 degrees of freedom for enhanced mobility, it is equipped with a multimodal visual sensing system on the head and torso, along with a dual-battery hot-swap system. It is well-suited for inspection, material handling, and assembly tasks.”TUOYUAN” industrial wheeled humanoid robot: Powered by an embodied intelligence foundation model and force-position hybrid control, it is capable of multi-spec connector insertion, material sorting, and loading/unloading of automotive sheet metal parts.”Mermaid” bionic wheeled humanoid robot: Capable of autonomously identifying buttons, knobs, and air switches, it generates real-time operation paths.Autonomous pipe inner-wall chamfering robot: Designed for confined spaces, it can position and process thousands of hole edges with accuracy within 1 millimeter while transmitting data in real time.

Shanghai Electric also showcased its portfolio of core components ranging from power-output to end effectors. Among them, the planetary roller screw offers more than three times the load capacity of traditional ball screws, while the DexHand dexterous hand is designed to meet diverse gripping and manipulation requirements.

Shanghai Electric launched 51 AI models and agents under its “StarCloud Intelligent Manufacturing” series across three domains: R&D and design, production and manufacturing, and operations and maintenance—covering critical equipment processes such as process optimization and wind power facility maintenance.

These industrial agents are embedded in robotic decision-making systems and the operational logic of AI-native smart factories, transforming industrial expertise into digitized, reusable capabilities. They support production-line scheduling, quality inspection, and predictive maintenance, driving the evolution of manufacturing systems from experience-driven to data-driven operations.

Shanghai Electric also released the “AI-Native Smart Factory Technology White Paper,” proposing an active evolution architecture that enables real‑time, closed‑loop optimization of production data, giving the factory self‑perception, self‑decision, and self‑execution capabilities. Built on First Principles, the AI‑native smart factory vertically integrates process flows, industrial software, agents, and smart equipment to dismantle traditional hierarchies while horizontally bridging data silos. The architecture features three core layers: the AI factory brain as the “control center,” industrial agents and embodied robots as the “execution network,” and the physical twin as the “digital mirror.”

Leveraging its deep industrial expertise and comprehensive solution capabilities, Shanghai Electric will continue to drive the implementation of AI in industrial settings, tackle technical challenges facing embodied intelligence in complex scenarios, accelerate the large‑scale deployment of AI‑native smart factories, and deliver replicable solutions across diverse manufacturing environments.

SOURCE Shanghai Electric

Continue Reading

Trending